en English
af Afrikaanssq Shqipam አማርኛar العربيةhy Հայերենaz Azərbaycan dilieu Euskarabe Беларуская моваbn বাংলাbs Bosanskibg Българскиca Catalàceb Cebuanony Chichewazh-CN 简体中文zh-TW 繁體中文co Corsuhr Hrvatskics Čeština‎da Dansknl Nederlandsen Englisheo Esperantoet Eestitl Filipinofi Suomifr Françaisfy Fryskgl Galegoka ქართულიde Deutschel Ελληνικάgu ગુજરાતીht Kreyol ayisyenha Harshen Hausahaw Ōlelo Hawaiʻiiw עִבְרִיתhi हिन्दीhmn Hmonghu Magyaris Íslenskaig Igboid Bahasa Indonesiaga Gaeligeit Italianoja 日本語jw Basa Jawakn ಕನ್ನಡkk Қазақ тіліkm ភាសាខ្មែរko 한국어ku كوردی‎ky Кыргызчаlo ພາສາລາວla Latinlv Latviešu valodalt Lietuvių kalbalb Lëtzebuergeschmk Македонски јазикmg Malagasyms Bahasa Melayuml മലയാളംmt Maltesemi Te Reo Māorimr मराठीmn Монголmy ဗမာစာne नेपालीno Norsk bokmålps پښتوfa فارسیpl Polskipt Portuguêspa ਪੰਜਾਬੀro Românăru Русскийsm Samoangd Gàidhligsr Српски језикst Sesothosn Shonasd سنڌيsi සිංහලsk Slovenčinasl Slovenščinaso Afsoomaalies Españolsu Basa Sundasw Kiswahilisv Svenskatg Тоҷикӣta தமிழ்te తెలుగుth ไทยtr Türkçeuk Українськаur اردوuz O‘zbekchavi Tiếng Việtcy Cymraegxh isiXhosayi יידישyo Yorùbázu Zulu

New Study: CyberKnife Effective for Treating Metastatic Lung Tumors

A recent study published in the Journal of Thoracic Disease presents data confirming CyberKnife® as a safe and effective treatment option for patients with metastatic lung cancer.

The study evaluated the efficacy and tolerability of CyberKnife for 95 patients with lung metastases. A total of 134 metastatic lung tumors were treated with stereotactic body radiation therapy (SBRT) using CyberKnife technology to observe local control and long-term survival and toxicity.

Over a period of three years, follow-ups with patients resulted in a 97.6% local control rate at the one-year mark, 90.6% at two-years and 87% at three-years. Median survival time was 38 months and median progression-free survival was 14 months. The two-year progression-free rate was 29% and overall survival was 61.3%. An overview of the study is available here.

Oklahoma CyberKnife treats primary and metastatic lung tumors with CyberKnife SBRT. Treatment does not require surgery or sedation and is completed in five or fewer outpatient sessions. If you have been diagnosed with metastatic lung cancer, contact Oklahoma CyberKnife to schedule a consultation and learn whether you may be a candidate for CyberKnife treatment.

This is not intended as medical advice to replace the expertise and judgment of your health care team. It is intended to help you and your family make informed decisions, together with your doctor.